109 completed, 46 active not recruiting, 33 recruiting, 22 terminated. 160 Phase 2, 88 Phase 1, 22 Phase 3, 6 Early Phase 1, 1 Not applicable.
Follow tremelimumab: new trials by email Literature Review of tremelimumab trials Research Report on tremelimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC) | Not yet recruiting | Assiut University | 294 | 2026-11-01 | 2026-10-29 | |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-10-01 | 2026-10-05 |
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2026-09-15 | 2026-08-06 |
| ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu Tremelimumab, Durvalumab - Solid Tumor, Adult, Malignant Solid Tumor | Early Phase 1 | Recruiting | University of California, Irvine | 34 | 2026-05-25 | 2026-07-07 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma RBS2418, STRIDE (durvalumab + tremelimumab) - Advanced Unresectable Hepatocellular Carcinoma | Phase 2 | Recruiting | Riboscience, LLC. | 220 | 2026-04-10 | 2026-04-24 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| IIT2025-03-YANG-LIFT-HCC STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA) - Hepato Cellular Carcinoma | Phase 2 | Recruiting | Ju Dong Yang | 41 | 2026-04-01 | 2026-03-27 |
| A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab SC durvalumab + rHu, IV durvalumab, Tremelimumab - Solid Tumours | Phase 1 | Recruiting | AstraZeneca | 40 | 2026-03-31 | 2026-09-24 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis Selective Internal Radiotherapy, Tremelimumab, Durvalumab - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Center Eugene Marquis | 80 | 2026-02-25 | 2026-05-05 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma Durvalumab Plus Tremelimumab, HAIC (GEMOX) - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Recruiting | UNICANCER | 196 | 2025-11-14 | 2026-02-03 |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma BC3402, Durvalumab, Tremelimumab - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2025-11-01 | 2026-02-19 | |
| STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma STRIDE (durvalumab + tremelimumab), Durvalumab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 140 | 2025-10-21 | 2026-08-11 |
| A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma Radiation Therapy, Tremelimumab, Durvalumab - Hepatocellular Carcinoma (HCC) | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2025-10-01 | 2025-11-18 | |
| Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Durvalumab, Tremelimumab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | AstraZeneca | 114 | 2025-08-05 | 2026-10-13 |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab - Biliary Tract Cancers | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2025-05-27 | 2026-05-08 |
| Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC Photon radiotherapy, Tremelimumab, Durvalumab - HCC - Hepatocellular Carcinoma, Tremelimumab | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 45 | 2025-05-22 | 2026-10-01 |
Showing 20 of 249. Sign in to see all of them.
Carcinoma, Hepatocellular (39) · Carcinoma, Non-Small-Cell Lung (24) · Melanoma (19) · Squamous Cell Carcinoma of Head and Neck (18) · Colorectal Neoplasms (16) · Breast Neoplasms (11) · Liver Neoplasms (11) · Urinary Bladder Neoplasms (11) · Biliary Tract Neoplasms (10) · Lung Neoplasms (10) · Carcinoma, Renal Cell (9) · Diabetes Mellitus, Insulin-Dependent, 12 (9) · Prostatic Neoplasms (9) · Small Cell Lung Carcinoma (9) · Neoplasms (8)
AstraZeneca (42) · MedImmune LLC (11) · Canadian Cancer Trials Group (10) · M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (8) · Memorial Sloan Kettering Cancer Center (7) · Ludwig Institute for Cancer Research (5) · Jonsson Comprehensive Cancer Center (4) · Seoul National University Hospital (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Chang Gung Memorial Hospital (3) · City of Hope Medical Center (3) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (3) · Pfizer (3)
United States (144) · Canada (43) · South Korea (40) · France (38) · Spain (35) · Germany (33) · Italy (33) · Taiwan (25) · United Kingdom (24) · Japan (20) · Netherlands (17) · Australia (16) · Belgium (16) · China (14) · Poland (14)
Tim F Greten, M.D. (5) · Haiyi Jiang, M.D. (3) · Arndt Vogel, Prof. Dr. (2) · Catherine Shu, MD (2) · Jaume Capdevila, M.D., Ph.D. (2) · Michele Maio, MD (2) · Samuel Funt, MD (2) · Sebastien Hotte (2) · Vassiliki Papadimitrakopoulou (2) · Aaron Hansen (1) · Abha Gupta (1)
PMID 18452610, PMID 20856802, PMID 21558401, PMID 23171508, PMID 23295794, PMID 24035405, PMID 24209604, PMID 24907635, PMID 25819643, PMID 26410619, PMID 26541610, PMID 26858122, PMID 27262113, PMID 27816492, PMID 28259287, PMID 28337197, PMID 28729154, PMID 28885881, PMID 28923358, PMID 29773326, PMID 29942666, PMID 30227886, PMID 30243800, PMID 30383184, PMID 30578687, PMID 30642290, PMID 30688989, PMID 30883000, PMID 31590988, PMID 31671191, PMID 31948903, PMID 32169783, PMID 32201234, PMID 32203306, PMID 32269052, PMID 32271377, PMID 32294530, PMID 32379280, PMID 32586937, PMID 32620213, PMID 32778095, PMID 32816849, PMID 32971005, PMID 33046869, PMID 33125909, PMID 33279854, PMID 33285097, PMID 33428583, PMID 33526329, PMID 33684371
2018 (9), 2017 (8), 2016 (7), 2015 (6), 2023 (3), 2008 (2), P30CA033572 (2), P30CA060553 (2), U10CA180868 (2), U10CA180888 (2), 2014 (1), 2019 (1), 2025 (1), P30CA015704 (1), P30CA016672 (1)